The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1B study of enzalutamide (ENZA) with or without sorafenib (SORA) in patients (pts) with advanced hepatocellular carcinoma (HCC).
 
James J. Harding
Consulting or Advisory Role - Bristol-Myers Squibb; CytomX Therapeutics; Lilly
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Incyte (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Polaris (Inst); Polaris (Inst)
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst)
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Exelixis (Inst); Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Regeneron (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Target Pharmasolutions (Inst); Tekmira (Inst)
 
Benjamin R. Tan
Consulting or Advisory Role - Roche/Genentech
Research Funding - Bayer; Boehringer Ingelheim; Eisai; Exelixis; Lilly; Merck Serono; Pfizer; Roche/Genentech; Sillajen; tyrogenex
 
Emily Iobst
No Relationships to Disclose
 
Chayma Boussayoud
No Relationships to Disclose
 
Kerri E. Muenkel
No Relationships to Disclose
 
Richard K. G. Do
No Relationships to Disclose
 
Joanne F. Chou
No Relationships to Disclose
 
Marinela Capanu
No Relationships to Disclose
 
Carmen Ruiz
No Relationships to Disclose
 
Mariam Rodriguez Lee
No Relationships to Disclose
 
John Wilton
No Relationships to Disclose
 
Renuka V. Iyer
Honoraria - Ipsen
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Eisai; Eisai; Ipsen; Lexicon; Merck; Merck; Novartis; Novartis
Research Funding - Cleveland BioLabs (Inst); Genentech/Roche (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Agios; Amgen; Antengene; Aptus Clinical; ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb (I); CARsgen Therapeutics; CASI Pharmaceuticals; Celgene; Celgene (I); Celsion; CytomX Therapeutics (I); Daiichi Sankyo; Debiopharm Group; Delcath Systems; Eisai; EMD Serono (I); Exelixis; Gilead Sciences (I); Halozyme; Halozyme (I); Inovio Pharmaceuticals; Ipsen; Medimmune; Merck Serono; Onxeo; PCI Biotech; Roche; Sanofi (I); SERVIER; Silenseed (I); Sillajen; Sirtex Medical; Sirtex Medical; Vicus Therapeutics (I); Yakult Pharmaceutical
Research Funding - Agios (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Exelixis (Inst); Genentech (Inst); Incyte (Inst); Lilly (Inst); MabVax (Inst); MedImmune (Inst); Momenta Pharmaceuticals (Inst); Novartis (Inst); OncoMed (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Polaris